The adjuvant effects of CpG motif and activated large number of activated-T lymphocytes on immunoresponses.

我们检测了CpG基序与HIV-DNA疫苗联合免疫或将大量活化的T细胞转移到疫苗免疫的同源小鼠是否能增强特异性免疫应答。对Balb/c小鼠联合接种CpG富集质粒和DNA疫苗可显著提高HIV特异性细胞免疫和体液免疫。含有最多拷贝数(20cpG)的质粒是最有效的免疫增强剂。在CD3抗体包被的培养瓶中，用IL-2培养正常BALB/c的脾细胞。流式细胞仪表型分析显示，该细胞群含有约60%的CD8+/Thy1.2+、18.5%的CD4+/Thy1.2+和8.9%的CD19+细胞。这些被激活的细胞通过ip途径转移到用HIV-DNA疫苗免疫的小鼠。结果表明，DNA疫苗接种后第2天，转移激活的T细胞可增强特异性细胞免疫和体液免疫。联合应用CpG基序和转移激活的T淋巴细胞均表现出较强的佐剂活性。这些佐剂方法不仅可以在人类人群中诱导HIV介导的免疫反应，还可以诱导其他传染病介导的免疫反应。这些给药可能对临床有益，因为它们简单，没有副作用和安全性。

We examined whether the co-administering the CpG motifs plasmid with HIV-DNA vaccine or the transfer of a large number of activated T cells to syngenic mice immunized with vaccine can augment the specific immune responses. Co-administering the CpG-enriched plasmids with a DNA vaccine to Balb/c mice significantly increased HIV-specific cell mediated and humoral immunity. Plasmids containg a most of number of copies (20 CpG) were the most effective immune enhancers. Spleen cells from normal BALB/c were cultured with IL-2 in the anti-mouse CD3 Ab-coated flask. The number of lymphocytes increased about 10-fold.Phenotyping analysis by flow cytometry showed, this cell population contained about 60% of CD8+/Thy1.2+, 18.5% of CD4+/Thy1.2 + and 8.9% of CD19 + cells. These activated cells were transferred via the I. p. route to mice immunized with HIV-DNA vaccine. Results indicated that transfer activated T cells 2 days after DNA vaccination increased specific cellular and humoral immunity. Both co-administering the CpG motif plasmid and the transfer activated T lymphocytes showed stronger adjuvant activity. These adjuvant methods may induce not only HIV-mediated immune responses but also other infectious diseases-mediated immune responses in the human population as well. These administrations are likely to be of clinical benefit because their simplicity, lack of side effects and safety.